Int J Med Rev 2024 June;11(2): 704-709

10.30491/IJMR.2024.455238.1280

INTERNATIONAL JOURNAL OF MEDICAL REVIEWS

Mini Review

A Brief Look at the Enigma of Protein Aggregation: Unraveling Mechanisms, Exploring Implications, and Proposing Therapeutic Strategies

Sirvan Abbasbeigi [1*]

[1] Islamic Azad University (IAU), Science and Research Branch, Sanandaj, Kurdistan, Iran

*** Corresponding Author:** Sirvan Abbasbeigi, Islamic Azad University (IAU), Science and Research Branch, Sanandaj, Kurdistan, Iran.

Received May 1, 2024; **Accepted** June 5, 2024; **Online Published** June 30, 2024

Abstract

Protein aggregation is a complex process that plays a key role in the development of various diseases, including neurodegenerative disorders, metabolic conditions, and systemic amyloidoses. This brief review summarizes the current understanding of the mechanisms behind protein aggregation, its impact on disease progression, and potential treatment approaches. We extensively researched recent influential publications, critically evaluated relevant articles, and synthesized key concepts, emerging trends, and promising research areas. Genetic mutations, environmental stress, and aging all contribute to the misfolding and aggregation of proteins. The aggregation process is influenced by thermodynamic and kinetic factors, involving stages such as nucleation, elongation, and the formation of aggregate structures. Biological systems, including molecular chaperones, the ubiquitin-proteasome pathway, and autophagy, play crucial roles in preventing and managing protein aggregates. Pathological protein aggregation is associated with diseases such as Alzheimer's, Parkinson's, prion diseases, cataracts, type II diabetes, and systemic amyloidoses. The review also emphasizes the potential of therapeutic strategies, such as small molecule inhibitors, immunotherapy, modulation of proteostasis pathways, nanotechnology, and gene therapy, in addressing these debilitating diseases. A comprehensive understanding of protein aggregation mechanisms and the development of effective therapeutic interventions offer hope in the fight against these diseases. This review provides current insights and recommends future research directions, highlighting the significant implications for human health and treatment innovation.

Keywords: Protein Aggregates, Neurodegenerative Diseases, Protein Folding, Amyloidosis, Molecular Chaperones, Therapeutics

Introduction

The Importance of Protein Folding Stability

Proteins are essential macromolecules that play crucial roles in all biological processes. The three-dimensional structure of a protein, known as its native conformation, is crucial for its proper biological function.[1] Proteins must fold into their unique native structures to effectively fulfill their intended roles.[2] Protein folding stability, which refers to the thermodynamic stability of the native conformation, is a key determinant of whether a protein can properly fold and function.[3]

Defining Protein Aggregation: from Oligomers to Amyloids

Protein aggregation is a phenomenon where misfolded or unfolded protein molecules associate with one another, forming larger and more complex structures.[4] This process can result in the formation of oligomers, protofibrils, fibrils, and, ultimately, amyloid structures.[5] Protein aggregation is often associated with losing a protein's native function and can lead to the formation of potentially toxic species.[6]

Prevalence of Protein Aggregation in Health and Disease

Protein aggregation is a widespread phenomenon that is observed in a variety of biological contexts.[7] A delicate balance is maintained in healthy cells between protein folding, misfolding, and aggregation, facilitated by a network of molecular chaperones and quality control mechanisms.[8] However, in certain disease states, such as neurodegenerative disorders, protein aggregation can become dysregulated, leading to the accumulation of toxic protein species and the onset of pathological conditions.[9]

Materials and Methods

The Aim and Procedure of the Present Study

The present study aimed to provide a comprehensive

overview of the current understanding of protein aggregation mechanisms and their implications for various diseases. The specific objectives were to:

i. Critically review the latest literature on factors influencing protein aggregation, including genetic mutations, environmental stress, and aging-related processes.
ii. Analyze protein aggregation's thermodynamic and kinetic aspects, highlighting the roles of nucleation, elongation, and aggregate structure formation.
iii. Evaluate the cellular mechanisms that prevent and manage protein aggregation, such as molecular chaperones, the ubiquitin-proteasome system, and autophagy pathways.
iv. Discuss the implications of protein aggregation in various pathological conditions, including neuro-degenerative diseases (e.g., Alzheimer's, Parkinson's, and prion diseases) and other disorders like cataracts, type II diabetes, and systemic amyloidoses.

Provide an overview of current and emerging therapeutic strategies targeting protein aggregation, including small-molecule inhibitors, immunotherapy approaches, and modulation of cellular proteostasis pathways.

Literature Search Strategy

A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science to achieve these objectives. The search strategy employed MeSH terms, including "Protein Aggregates", "Neurodegenerative Diseases", "Protein Folding", "Amyloidosis", "Molecular Chaperones", and "Therapeutics". Articles published in high-impact peer-reviewed journals within the last five years were prioritized to ensure the review reflected recent developments in the field.

Inclusion and Exclusion Criteria

The inclusion criteria were: A) original research articles, reviews, and meta-analyses; B) publications focusing on the mechanisms of protein aggregation, disease implications, and therapeutic strategies; C) articles available in English. However, Exclusion criteria included: A) papers unrelated to the specified objectives; B) studies published more than five years ago, unless they were seminal works essential for context; C) non-peer-reviewed literature.

Data Collection and Analysis

The selected articles were carefully chosen and reviewed. We identified key themes, emerging trends, and potential controversies or knowledge gaps. Each study was evaluated for its methodological quality and relevance to the review's objectives. We extracted data on factors influencing protein aggregation, thermodynamic and kinetic properties, cellular mechanisms, disease implications, and therapeutic strategies.

Scoping Review Approach & Interdisciplinary Integration

A scoping review approach was employed to organize and interpret the diverse findings. This involved mapping key concepts, theories, evidence sources, and literature gaps. Connections between different aspects of protein aggregation and their relevance to disease pathogenesis were drawn based on the synthesized data.Insights from various disciplines, including biochemistry, biophysics, cell biology, and structural biology, were integrated to provide a comprehensive and interdisciplinary understanding of protein aggregation.

Study Limitations and Directions vs. Objective and Contribution

Throughout the evaluation, a balanced perspective was maintained by highlighting the strengths and limitations of current research. Potential avenues for future investigation were identified to address gaps and controversies in the existing literature.The ultimate goal of this mini-review is to serve as a valuable resource for researchers, clinicians, and other stakeholders interested in protein aggregation and its implications for human health and disease.

Discussion

Mechanisms of Protein Aggregation

Factors Influencing Aggregation: Mutations, Environmental Stress, and Aging

Protein aggregation is a complex process influenced by various factors, including genetic mutations, environmental stress, and aging.[10] Mutations in the protein sequence can destabilize the native structure, increasing the propensity for misfolding and aggregation.[11] Environmental factors such as elevated temperatures, oxidative stress, and changes in pH can also promote protein unfolding and subsequent

aggregation.[12] Additionally, the aging process can contribute to protein aggregation due to the accumulation of oxidative damage, impaired protein quality control mechanisms, and decreased efficiency of molecular chaperones.[13]

Thermodynamic and Kinetic Aspects of Aggregation

Both thermodynamic and kinetic factors govern protein aggregation.[14] From a thermodynamic perspective, aggregation is favored when the aggregated state is more stable than the soluble, monomeric state.[15] However, kinetic factors, such as the rate of nucleation and elongation, are crucial in determining the overall aggregation pathway and the formation of specific aggregate structures. Various parameters, including protein concentration, temperature, and the presence of aggregation seeds or preformed aggregates, influence these kinetic factors.[16]

The Role of Molecular Chaperones in Preventing Aggregation

Molecular chaperones are a class of proteins that play a vital role in maintaining protein homeostasis (proteostasis) and preventing protein aggregation.[17] They assist in properly folding nascent polypeptide chains and can refold or sequester misfolded proteins, thereby preventing their aggregation. Chaperones such as Hsp70 and Hsp90 are involved in various protein quality control mechanisms, and their dysfunction has been implicated in the pathogenesis of protein aggregation diseases.[18]

Cellular Mechanisms for Handling Protein Aggregates: Degradation Pathways

Cells have evolved various mechanisms to handle and clear protein aggregates. The ubiquitin-proteasome system (UPS) and autophagy are the two major degradation pathways responsible for removing misfolded and aggregated proteins.[19] The UPS targets individual misfolded proteins for degradation, while autophagy can degrade larger protein aggregates and organelles. Impairment of these degradation pathways can accumulate protein aggregates and contribute to the pathogenesis of various diseases.[20]

Implications of Protein Aggregation

Loss of Protein Function and Cellular Toxicity

Protein aggregation can lead to a loss of protein function as the aggregated proteins are sequestered and unable to perform their normal cellular roles.[4,11] This can disrupt various cellular processes and pathways, leading to cellular dysfunction and toxicity.[21] Some protein aggregates can directly interact with cellular components and membranes, causing oxidative stress, disruption of organelle function, and impairment of protein trafficking.[22,23]

Protein Aggregation in Neurodegenerative Diseases: Alzheimer's, Parkinson's, and Prion Diseases

Protein aggregation is a hallmark of several neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and prion diseases.[24] In AD, the amyloid-β peptide and tau protein form insoluble aggregates known as amyloid plaques and neurofibrillary tangles, respectively. In PD, the aggregation of α-synuclein leads to the formation of Lewy bodies.[25] Prion diseases are caused by the misfolding and aggregation of prion proteins, which can propagate their abnormal conformations and trigger further aggregation.[26]

Aggregation in Other Diseases: Cataracts, Type II Diabetes, and Systemic Amyloidosis

Protein aggregation is not limited to neuro-degenerative diseases.[27] In cataracts, the crystallin proteins in the eye lens form insoluble aggregates, leading to lens opacity and vision impairment.[28] Type II diabetes is associated with islet amyloid polypeptide (IAPP) aggregation, which can disrupt pancreatic β-cell function.[29] Systemic amyloidoses are a group of disorders characterized by the deposition of amyloid fibrils derived from various proteins, such as immunoglobulin light chains or transthyretin, in various tissues and organs.[30]

The Link Between Protein Aggregation and Aging

Protein aggregation has been implicated in aging, and accumulating aggregated proteins is a hallmark of cellular and organismal aging.[31] As organisms age, cellular protein quality control mechanisms become less efficient, increasing the burden of misfolded and aggregated proteins.[32] Additionally, accumulating oxidative damage and other age-related stresses can further promote protein aggregation.[33] This link between protein aggregation and aging suggests that targeting protein homeostasis may be a potential

strategy for promoting healthy aging.[34]

Therapeutic Strategies Targeting Protein Aggregation

Inhibiting Aggregation: Small Molecule Inhibitors and Aggregation Suppressors

One therapeutic approach to addressing protein aggregation involves using small-molecule inhibitors and aggregation suppressors.[35] These compounds can interact with monomeric or oligomeric protein species, stabilizing their native conformations or redirecting the aggregation pathway toward the formation of non-toxic aggregates.[36] Examples include molecular tweezers, polyphenols, and other small molecules that have shown promising results in preclinical studies for various protein aggregation diseases.[21,37]

Promoting Disaggregation and Clearance of Aggregates: Chemical Chaperones and Immunotherapy Approaches

Another strategy involves promoting the disaggregation and clearance of existing protein aggregates.[38] Chemical chaperones, such as glycerol and trehalose, can stabilize protein structures and facilitate the refolding or disaggregation of misfolded proteins.[39] Immunotherapy approaches, including active and passive immunization, aim to induce or provide antibodies that can recognize and promote the clearance of protein aggregates.[40]

Targeting the Cellular Machinery: Enhancing Proteostasis and Degradation Pathways

Targeting the cellular machinery involved in protein quality control and degradation is another approach to combating protein aggregation.[41] Upregulating molecular chaperones or enhancing the ubiquitin-proteasome system's (UPS) activity and autophagy pathways can improve the cell's ability to handle misfolded and aggregated proteins.[42] Small molecules and genetic manipulations have been explored to modulate these pathways and promote proteostasis.[43]

Emerging Strategies: Nanotechnology and Gene Therapy

Nanotechnology and gene therapy represent emerging strategies in protein aggregation therapeutics.[44] Nanoparticles and nanomaterials can be engineered to interact with and modulate protein aggregation processes.[45] Gene therapy approaches aim to deliver therapeutic genes or modulate the expression of genes involved in protein aggregation diseases, offering the potential for long-term treatment.[46]

Conclusion and Future Perspectives

Recap of Key Points and Challenges in the Field

Protein aggregation is a complex and multifaceted phenomenon that underlies the pathogenesis of various diseases, including neurodegenerative disorders, metabolic diseases, and systemic amyloidoses. Understanding the mechanisms governing protein aggregation, such as the interplay between genetic mutations, environmental factors, and aging, is crucial for developing effective therapeutic interventions.

While significant progress has been made in elucidating the molecular details of aggregation processes and their implications for disease pathogenesis, several challenges remain. These include the heterogeneity of aggregation pathways, the difficulty in targeting specific aggregate species, and the need for better cellular and animal models to study protein aggregation diseases.

Promising Avenues for Research and Development

Several promising avenues for future research and development in the field of protein aggregation can be identified:

i. Continued exploration of the molecular mechanisms underlying protein aggregation, including the roles of cellular quality control pathways and the interplay between different aggregation-prone proteins.
ii. Development of more sensitive and specific diagnostic tools for early protein aggregation detection, enabling earlier intervention and improved disease management.
iii. Advancement of high-throughput screening technologies for identifying and optimizing small molecule inhibitors, aggregation suppressors, and other therapeutic agents targeting protein aggregation.
iv. Exploration of combination therapies that simultaneously target multiple aspects of protein aggregation, such as inhibiting aggregation, promoting disaggregation, and enhancing clearance mechanisms.
v. Leveraging emerging technologies like nanotechnology and gene therapy for more targeted and effective delivery of therapeutic agents to affected tissues

and cells.

Continued efforts in translational research to bridge the gap between preclinical studies and clinical trials facilitating faciliate the development of new treatments for protein aggregation diseases.

Potential Impact on Human Health and Disease Treatment

The successful development of therapeutic strategies targeting protein aggregation has the potential to impact human health and disease treatment significantly. By addressing the underlying mechanisms of protein misfolding and aggregation, these approaches could potentially halt or reverse the progression of devastating diseases like Alzheimer's, Parkinson's, and other neurodegenerative disorders.

Moreover, targeting protein aggregation could also benefit patients suffering from non-neurological diseases, such as cataracts, type II diabetes, and systemic amyloidoses, where protein aggregation plays a crucial role in disease pathogenesis.

Furthermore, as protein aggregation has been linked to the aging process, interventions targeting this phenomenon could potentially promote healthy aging and improve the overall quality of life for the aging population.

Ultimately, the successful development of therapies targeting protein aggregation would represent a significant advancement in our ability to combat a wide range of debilitating diseases, potentially improving the lives of millions of people worldwide.

Conflict of Interest

The author declares no conflicts of interest.

References

1. Stollar EJ, Smith DP. Uncovering protein structure. Essays Biochem. 2020;64(4):649-80. doi:10.1042/EBC20190042
2. Poluri KM, Gulati K, Sarkar S, Poluri KM, Gulati K, Sarkar S. Structural and functional properties of proteins. Protein-Protein Interactions: Principles and Techniques: Volume I. 2021:1-60. doi:10.1007/978-981-16-1594-8_1
3. Sorokina I, Mushegian AR, Koonin EV. Is protein folding a thermodynamically unfavorable, active, energy-dependent process? Int J Mol Sci. 2022;23(1):521. doi:10.3390/ijms23010521
4. Ajmal MR. Protein misfolding and aggregation in proteinopathies: causes, mechanism and cellular response. Diseases. 2023;11(1):30. doi:10.3390/diseases11010030
5. Almeida ZL, Brito RM. Structure and aggregation mechanisms in amyloids. Molecules. 2020;25(5):1195. doi:10.3390/molecules25051195
6. Ezzat K, Sturchio A, Espay AJ. Proteins do not replicate, they precipitate: Phase transition and loss of function toxicity in amyloid pathologies. Biology. 2022;11(4):535. doi:10.3390/biology11040535
7. Dobson CM, Knowles TP, Vendruscolo M. The amyloid phenomenon and its significance in biology and medicine. Cold Spring Harb Perspect Biol. 2020;12(2):a033878. doi:10.1016/j.semcdb.2018.05.003
8. Hervás R, Oroz J. Mechanistic insights into the role of molecular chaperones in protein misfolding diseases: from molecular recognition to amyloid disassembly. Int J Mol Sci. 2020;21(23):9186. doi:10.3390/ijms21239186
9. Candelise N, Scaricamazza S, Salvatori I, Ferri A, Valle C, Manganelli V, et al. Protein aggregation landscape in neurodegenerative diseases: clinical relevance and future applications. Int J Mol Sci. 2021;22(11):6016. doi:10.3390/ijms22116016
10. Wen JH, He XH, Feng ZS, Li DY, Tang JX, Liu HF. Cellular protein aggregates: formation, biological effects, and ways of elimination. Int J Mol Sci. 2023;24(10):8593. doi:10.3390/ijms24108593
11. Louros N, Schymkowitz J, Rousseau F. Mechanisms and pathology of protein misfolding and aggregation. Nat Rev Mol Cell Biol. 2023;24(12):912-33. doi:10.1038/s41580-023-00647-2
12. Zhang Y, Liu G, Xie Q, Wang Y, Yu J, Ma X. Physicochemical and structural changes of myofibrillar proteins in muscle foods during thawing: Occurrence, consequences, evidence, and implications. Compr Rev Food Sci Food Saf. 2023;22(4):3444-77. doi:10.1111/1541-4337.13194
13. Ahanger IA, Ashraf GM, Sharma A, Islam A. Comprehensive perspective towards the management of proteinopathies by elucidating protein misfolding and aggregation. CNS Neurol Disord Drug Targets. 2024;23(2):153-80. doi:10.2174/1871527322666230306085937
14. Panda C, Kumar S, Gupta S, Pandey LM. Structural, kinetic, and thermodynamic aspects of insulin aggregation. Phys Chem Chem Phys. 2023. doi:10.1039/D3CP03103A
15. Patni D, Jha SK. Thermodynamic modulation of folding and aggregation energy landscape by DNA binding of functional domains of TDP-43. Biochim Biophys Acta - Proteins Proteom. 2023;1871(4):140916. doi:10.1016/j.bbapap.2023.140916
16. Housmans JA, Wu G, Schymkowitz J, Rousseau F. A guide to studying protein aggregation. FEBS J. 2023;290(3):554-83. doi:10.1111/febs.16312
17. Hendershot LM, Buck TM, Brodsky JL. The Essential Functions of Molecular Chaperones and Folding Enzymes in Maintaining Endoplasmic Reticulum Homeostasis. J Mol Biol. 2023:168418. doi:10.1016/j.jmb.2023.168418
18. Singh MK, Shin Y, Ju S, Han S, Choe W, Yoon KS, et al. Heat Shock Response and Heat Shock Proteins: Current Understanding and Future Opportunities in Human Diseases. Int J Mol Sci. 2024;25(8):4209. doi:10.3390/ijms25084209
19. Yu P, Hua Z. To Kill or to Be Killed: How Does the Battle between the UPS and Autophagy Maintain the Intracellular Homeostasis in Eukaryotes? Int J Mol Sci. 2023;24(3):2221. doi:10.3390/ijms24032221
20. Amirian R, Badrbani MA, Derakhshankhah H, Izadi Z, Shahbazi M-A. Targeted protein degradation for the treatment of Parkinson's disease: Advances and future perspective. Biomed Pharmacother. 2023;166:115408. doi:10.1016/j.biopha.2023.115408
21. Abbasbeigi S, Adibi H, Moradi S, Ghadami SA, Khodarahmi R. Detection/quantification of amyloid aggregation in solution using the novel fluorescent benzofuranone-derivative compounds as amyloid fluorescent probes: synthesis and in vitro characterization. J Iran Chem Soc. 2019;16:1225-37. doi:10.1007/s13738-019-01599-1
22. Abbasbeigi S. Misfolded structures| A brief insight into protein aggregation criteria, which may lead to Proteopathy diseases. J Chem Rev. 2020;3(1):97-108. doi:10.22034/jcr.2020.256367.1092
23. Abbasbeigi S. A Comprehensive Review of the Aggregated Proteins through Routine Optical Studies Aiming to be Replaced by Aurone-specific Derivatives. Int J Med Rev. 2022;9(3):322-32. doi:10.30491/ijmr.2021.282160.1201
24. Wilson DM, Cookson MR, Van Den Bosch L, Zetterberg H, Holtzman DM, Dewachter I. Hallmarks of neurodegenerative diseases. Cell. 2023;186(4):693-714. doi:10.1016/j.cell.2022.12.032
25. Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein

aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022;214: 102270. doi:10.1016/j.pneurobio.2022.102270
26. Lukiw WJ. Recent advances in our molecular and mechanistic understanding of misfolded cellular proteins in Alzheimer's disease (AD) and prion disease (PrD). Biomolecules. 2022; 12(2):166. doi:10.3390/biom12020166
27. Lupaescu A-V, Iavorschi M, Covasa M. The use of bioactive compounds in hyperglycemia-and amyloid fibrils-induced toxicity in type 2 diabetes and Alzheimer's disease. Pharmaceutics. 2022;14(2):235. doi:10.3390/pharmaceutics 14020235
28. Budnar P, Tangirala R, Bakthisaran R, Rao CM. Protein aggregation and cataract: role of age-related modifications and mutations in α-crystallins. Biochemistry. 2022;87(3):225-41. doi:10.1134/S000629792203004X
29. Roham PH, Save SN, Sharma S. Human islet amyloid polypeptide: A therapeutic target for the management of type 2 diabetes mellitus. J Pharm Anal. 2022;12(4):556-69. doi:10.10 16/j.jpha.2022.04.001
30. Goldis R, Kaplan B, Kukuy O, Arad M, Magen H, Shavit-Stein E, et al. Diagnostic Challenges and Solutions in Systemic Amyloidosis. Int J Mol Sci. 2023;24(5):4655. doi:10.3390/ ijms24054655
31. Cuanalo-Contreras K, Schulz J, Mukherjee A, Park K-W, Armijo E, Soto C. Extensive accumulation of misfolded protein aggregates during natural aging and senescence. Front Aging Neurosci. 2023;14:1090109. doi:10.3389/fnagi.2022.1090109
32. Sarkar A, Nazir A. Carrying excess baggage can slowdown life: protein clearance machineries that go awry during aging and the relevance of maintaining them. Mol Neurobiol. 2022;59(2):821-40. doi:10.1007/s12035-021-02640-2
33. Zavadskiy S, Sologova S, Moldogazieva N. Oxidative distress in aging and age-related diseases: Spatiotemporal dysregulation of protein oxidation and degradation. Biochimie. 2022;195:114-34. doi:10.1016/j.biochi.2021.12.002
34. Di Domenico F, Lanzillotta C. The disturbance of protein synthesis/degradation homeostasis is a common trait of age-related neurodegenerative disorders. Adv Protein Chem Struct Biol. 2022;132:49-87. doi:10.1016/bs.apcsb.2022.05.008
35. Wu H, Yao H, He C, Jia Y, Zhu Z, Xu S, et al. Molecular glues modulate protein functions by inducing protein aggregation: A promising therapeutic strategy of small molecules for disease treatment. Acta Pharmaceutica Sinica B. 2022;12(9):3548-66. doi:10.1016/j.apsb.2022.03.019
36. Galzitskaya OV, Grishin SY, Glyakina AV, Dovidchenko NV, Konstantinova AV, Kravchenko SV, et al. The Strategies of Development of New Non-Toxic Inhibitors of Amyloid Formation. Int J Mol Sci. 2023;24(4):3781. doi:10.3390/ ijms24043781
37. Peña-Díaz S, García-Pardo J, Ventura S. Development of small molecules targeting α-synuclein aggregation: a promising strategy to treat Parkinson's disease. Pharmaceutics. 2023;15(3):839. doi:10.3390/pharmaceutics15030839
38. Schneider KL, Ahmadpour D, Keuenhof KS, Eisele-Bьrger AM, Berglund LL, Eisele F, et al. Using reporters of different misfolded proteins reveals differential strategies in processing protein aggregates. J Biol Chem. 2022;298(11). doi:10.1016/ j.jbc.2022.102476
39. Singh R, Kaur N, Dhingra N, Kaur T. Protein misfolding, ER stress and chaperones: An approach to develop chaperone-based therapeutics for Alzheimer's disease. Int J Neurosci. 2023;133(7):714-34. doi:10.1080/00207454.2021.1968859
40. Alshamrani M. Recent trends in active and passive immunotherapies of Alzheimer's disease. Antibodies. 2023; 12(2):41. doi:10.3390/antib12020041
41. Chen G, Wei T, Ju F, Li H. Protein quality control and aggregation in the endoplasmic reticulum: from basic to bedside. Front Cell Dev Biol. 2023;11:1156152. doi:10.3389/ fcell.2023.1156152
42. Li Y, Li S, Wu H. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress. Cells. 2022;11(5):851. doi:10.3390/ cells11050851
43. Kulkarni A, Preeti K, Tryphena KP, Srivastava S, Singh SB, Khatri DK. Proteostasis in Parkinson's disease: Recent development and possible implication in diagnosis and therapeutics. Ageing Res Rev. 2023;84:101816. doi:10.1016/ j.arr.2022.101816
44. Jain U, Johari S, Srivastava P. Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer's Disease. Mol Neurobiol. 2023:1-21. doi:10.1007/s12035-023-03671-7
45. Kaltbeitzel J, Wich PR. Protein-based Nanoparticles: From Drug Delivery to Imaging, Nanocatalysis and Protein Therapy. Angew Chem Int Ed Engl. 2023;62(44):e202216097. doi:10.1002/anie.202216097
46. Ataei B, Hokmabadi M, Asadi S, Asadifard E, Zarch SMA, Najafi S, et al. A review of the advances, insights, and prospects of gene therapy for Alzheimer's disease: A novel target for therapeutic medicine. Gene. 2024:148368. doi:10.1016/j.gene.2024.148368